1002 related articles for article (PubMed ID: 19264687)
1. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
2. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
Flood-Page P; Swenson C; Faiferman I; Matthews J; Williams M; Brannick L; Robinson D; Wenzel S; Busse W; Hansel TT; Barnes NC;
Am J Respir Crit Care Med; 2007 Dec; 176(11):1062-71. PubMed ID: 17872493
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma.
Dente FL; Bacci E; Bartoli ML; Cianchetti S; Costa F; Di Franco A; Malagrinò L; Vagaggini B; Paggiaro P
Ann Allergy Asthma Immunol; 2010 Jun; 104(6):464-70. PubMed ID: 20568377
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab and exacerbations of refractory eosinophilic asthma.
Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
[TBL] [Abstract][Full Text] [Related]
5. Inhaled fluticasone propionate is effective as well as oral prednisone in reducing sputum eosinophilia during exacerbations of asthma which do not require hospitalization.
Di Franco A; Bacci E; Bartoli ML; Cianchetti S; Dente FL; Taccola M; Vagaggini B; Zingoni M; Paggiaro PL
Pulm Pharmacol Ther; 2006; 19(5):353-60. PubMed ID: 16289980
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations.
Belda J; Margarit G; Martínez C; Bellido-Casado J; Casan P; Torrejón M; Brufal M; Rodríguez-Jerez F; Sanchis J
Eur Respir J; 2007 Dec; 30(6):1143-9. PubMed ID: 17690122
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
[TBL] [Abstract][Full Text] [Related]
8. Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma.
Jayaram L; Duong M; Pizzichini MM; Pizzichini E; Kamada D; Efthimiadis A; Hargreave FE
Eur Respir J; 2005 Jan; 25(1):41-6. PubMed ID: 15640321
[TBL] [Abstract][Full Text] [Related]
9. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
[TBL] [Abstract][Full Text] [Related]
10. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
11. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
12. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
Milgrom H; Fick RB; Su JQ; Reimann JD; Bush RK; Watrous ML; Metzger WJ
N Engl J Med; 1999 Dec; 341(26):1966-73. PubMed ID: 10607813
[TBL] [Abstract][Full Text] [Related]
13. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
15. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
Straumann A; Conus S; Grzonka P; Kita H; Kephart G; Bussmann C; Beglinger C; Smith DA; Patel J; Byrne M; Simon HU
Gut; 2010 Jan; 59(1):21-30. PubMed ID: 19828470
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab treatment for asthma.
Robinson DS
Expert Opin Biol Ther; 2013 Feb; 13(2):295-302. PubMed ID: 22998420
[TBL] [Abstract][Full Text] [Related]
18. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.
Oldhoff JM; Darsow U; Werfel T; Katzer K; Wulf A; Laifaoui J; Hijnen DJ; Plötz S; Knol EF; Kapp A; Bruijnzeel-Koomen CA; Ring J; de Bruin-Weller MS
Allergy; 2005 May; 60(5):693-6. PubMed ID: 15813818
[TBL] [Abstract][Full Text] [Related]
19. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
20. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
